Back to Search
Start Over
Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon- : 5-year outcome
- Source :
- Haematologica. 93:770-774
- Publication Year :
- 2008
- Publisher :
- Ferrata Storti Foundation (Haematologica), 2008.
-
Abstract
- In 2004, we reported the short-term results of a multicentric, phase 2 study of imatinib 400 mg daily and pegylated interferon-alpha in the treatment of 76 early chronic phase Philadelphia-positive chronic myeloid leukemia patients. In this report, we update the results with an observation time of five years. After two years of treatment, all but 10 patients (13%) had discontinued pegylated interferon-alpha. The complete cytogenetic response rate at five years was 87%, and 94% of complete cytogenetic responders maintained the complete cytogenetic response after five years. All but one complete cytogenetic response also achieved a major molecular response. These data confirm the excellent response to imatinib front-line and the stability of the complete cytogenetic response. Any possible additional benefit of the combination with interferon-alpha remains uncertain, due to low patient compliance.
- Subjects :
- Oncology
medicine.medical_specialty
Time Factors
Phases of clinical research
Alpha interferon
IMATINIB
Disease-Free Survival
Piperazines
Cohort Studies
Chronic myeloid leukemia
Imatinib
Interferon-alpha
Long-term results
Antineoplastic Combined Chemotherapy Protocols
Benzamides
Cytogenetics
Follow-Up Studies
Humans
Imatinib Mesylate
Immunologic Factors
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Patient Compliance
Pyrimidines
Treatment Outcome
Hematology
Pegylated interferon
Internal medicine
medicine
Chronic
Interferon alfa
CHRONIC MYELOID LEUKEMIA
Leukemia
business.industry
Myeloid leukemia
medicine.disease
Imatinib mesylate
Immunology
BCR-ABL Positive
business
Myelogenous
medicine.drug
Chronic myelogenous leukemia
Subjects
Details
- ISSN :
- 15928721 and 03906078
- Volume :
- 93
- Database :
- OpenAIRE
- Journal :
- Haematologica
- Accession number :
- edsair.doi.dedup.....b89ef090eb4fe1036e211b13f1f49aca